[K-Bio Big Data Awards] Quantum Jump in Corporate Value... Approaching the 1 Trillion Won Club

Minister of Health and Welfare Award - Samsung Biologics

Kim Tae-han, CEO of Samsung Biologics

[Asia Economy Reporter Seo So-jung] The Minister of Health and Welfare Award was given this year to Samsung Biologics, which has expanded the horizon of K-Bio by increasing overseas orders. Since entering the bio business in 2011 with the contract manufacturing organization (CMO) business for biopharmaceuticals, Samsung Biologics secured the top global CMO position this year, nine years after its establishment. This year, it achieved CMO orders worth approximately 1.8 trillion KRW from global pharmaceutical companies such as GSK and AstraZeneca, and also signed contracts for a cumulative total of 60 contract development organization (CDO) service projects.

This performance was also reflected in big data analysis. Stock-related keywords such as 'KOSPI', 'index', 'rise', and 'foreigners' frequently appeared, indicating interest in the increase of corporate value. In March this year, despite the global stock market crash caused by the worldwide spread of the novel coronavirus infection (COVID-19), Samsung Biologics quickly recovered its stock price and was recognized as a company with short-term stock price gains.

Although the global stock market was shocked in a short period, Samsung Biologics was mentioned with positive keywords in the stock market as a leading bio and pharmaceutical company. Continuous purchases by foreigners and institutions drove the stock price up. Lee Jae-yong, Vice Chairman of Samsung Electronics, was also mentioned as a key keyword, reflecting the fact that the bio business is recognized as Samsung's core business responsible for future growth.

Along with active overseas orders, solid performance supported the increase in corporate value, which was evaluated as enhancing brand value. Samsung Biologics became capable of joining the 1 trillion KRW club this year. With cumulative sales of 789.5 billion KRW and operating profit of 200.2 billion KRW in the third quarter, it exceeded last year's total sales and operating profit. At the end of last month, it opened a 612,000-pyeong scale contract development organization (CDO) research and development (R&D) center in San Francisco, the largest bio cluster in the United States, entering the U.S. market. This month, the groundbreaking ceremony for the world's largest production facility, Plant 4, will be held. When the Incheon Songdo Plant 4, with a capacity of 256,000 liters, is completed in 2023, Samsung Biologics will handle about 30% of the global biopharmaceutical volume.

This content was produced with the assistance of AI translation services.